Our model reveals clinical features that should be considered when deciding to initiate GLP-1 M combined therapy for the treatment of T2D, including age, race, T2D duration, HbA1C levels, BMI, hypertension, and the presence or absence of heart failure or retinopathy. Here, GCG is linked to hypertensive disorder.